nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—CYP2A6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00529	0.0596	CbGpPWpGaD
Formoterol—Melaena—Doxorubicin—bone cancer	0.00328	0.0036	CcSEcCtD
Formoterol—Cystitis noninfective—Doxorubicin—bone cancer	0.00328	0.0036	CcSEcCtD
Formoterol—Cystitis—Doxorubicin—bone cancer	0.00324	0.00356	CcSEcCtD
Formoterol—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00322	0.0363	CbGpPWpGaD
Formoterol—Candida infection—Doxorubicin—bone cancer	0.00321	0.00352	CcSEcCtD
Formoterol—Immune system disorder—Cisplatin—bone cancer	0.00321	0.00352	CcSEcCtD
Formoterol—Mediastinal disorder—Cisplatin—bone cancer	0.0032	0.00351	CcSEcCtD
Formoterol—Arrhythmia—Cisplatin—bone cancer	0.00317	0.00348	CcSEcCtD
Formoterol—Abnormal vision—Epirubicin—bone cancer	0.00317	0.00348	CcSEcCtD
Formoterol—Malnutrition—Cisplatin—bone cancer	0.00309	0.00339	CcSEcCtD
Formoterol—Cramps of lower extremities—Doxorubicin—bone cancer	0.00309	0.00339	CcSEcCtD
Formoterol—CYP2A6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00305	0.0344	CbGpPWpGaD
Formoterol—Neoplasm—Doxorubicin—bone cancer	0.00304	0.00333	CcSEcCtD
Formoterol—Bladder pain—Doxorubicin—bone cancer	0.00304	0.00333	CcSEcCtD
Formoterol—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00298	0.0336	CbGpPWpGaD
Formoterol—Muscle spasms—Cisplatin—bone cancer	0.00297	0.00326	CcSEcCtD
Formoterol—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00296	0.0334	CbGpPWpGaD
Formoterol—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00294	0.0331	CbGpPWpGaD
Formoterol—Abnormal vision—Doxorubicin—bone cancer	0.00293	0.00322	CcSEcCtD
Formoterol—Cardiac failure congestive—Epirubicin—bone cancer	0.00291	0.00319	CcSEcCtD
Formoterol—Tremor—Cisplatin—bone cancer	0.0029	0.00318	CcSEcCtD
Formoterol—Ill-defined disorder—Cisplatin—bone cancer	0.00287	0.00315	CcSEcCtD
Formoterol—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00281	0.0317	CbGpPWpGaD
Formoterol—Malaise—Cisplatin—bone cancer	0.00279	0.00306	CcSEcCtD
Formoterol—Hypoglycaemia—Epirubicin—bone cancer	0.0027	0.00296	CcSEcCtD
Formoterol—Cardiac failure congestive—Doxorubicin—bone cancer	0.00269	0.00295	CcSEcCtD
Formoterol—Myalgia—Cisplatin—bone cancer	0.00263	0.00289	CcSEcCtD
Formoterol—Anxiety—Cisplatin—bone cancer	0.00262	0.00288	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00261	0.00287	CcSEcCtD
Formoterol—Discomfort—Cisplatin—bone cancer	0.0026	0.00285	CcSEcCtD
Formoterol—CYP2A6—Xenobiotics—CYP3A4—bone cancer	0.00255	0.0288	CbGpPWpGaD
Formoterol—Anaphylactic shock—Cisplatin—bone cancer	0.00252	0.00277	CcSEcCtD
Formoterol—Oedema—Cisplatin—bone cancer	0.00252	0.00277	CcSEcCtD
Formoterol—Infection—Cisplatin—bone cancer	0.00251	0.00275	CcSEcCtD
Formoterol—Hypoglycaemia—Doxorubicin—bone cancer	0.0025	0.00274	CcSEcCtD
Formoterol—Nervous system disorder—Cisplatin—bone cancer	0.00247	0.00271	CcSEcCtD
Formoterol—Tachycardia—Cisplatin—bone cancer	0.00246	0.0027	CcSEcCtD
Formoterol—CYP2A6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00245	0.0277	CbGpPWpGaD
Formoterol—Dehydration—Epirubicin—bone cancer	0.00245	0.00269	CcSEcCtD
Formoterol—Skin disorder—Cisplatin—bone cancer	0.00245	0.00269	CcSEcCtD
Formoterol—Asthma—Methotrexate—bone cancer	0.00243	0.00267	CcSEcCtD
Formoterol—Dry skin—Epirubicin—bone cancer	0.00242	0.00265	CcSEcCtD
Formoterol—Hypokalaemia—Epirubicin—bone cancer	0.0024	0.00263	CcSEcCtD
Formoterol—Hypotension—Cisplatin—bone cancer	0.00236	0.00259	CcSEcCtD
Formoterol—Nasopharyngitis—Epirubicin—bone cancer	0.00236	0.00259	CcSEcCtD
Formoterol—Gastritis—Epirubicin—bone cancer	0.00233	0.00256	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Cisplatin—bone cancer	0.0023	0.00252	CcSEcCtD
Formoterol—Asthma—Epirubicin—bone cancer	0.00228	0.0025	CcSEcCtD
Formoterol—Influenza—Epirubicin—bone cancer	0.00228	0.0025	CcSEcCtD
Formoterol—Dehydration—Doxorubicin—bone cancer	0.00227	0.00249	CcSEcCtD
Formoterol—Upper respiratory tract infection—Methotrexate—bone cancer	0.00226	0.00248	CcSEcCtD
Formoterol—Dyspnoea—Cisplatin—bone cancer	0.00225	0.00247	CcSEcCtD
Formoterol—Dry skin—Doxorubicin—bone cancer	0.00224	0.00245	CcSEcCtD
Formoterol—Hypokalaemia—Doxorubicin—bone cancer	0.00222	0.00244	CcSEcCtD
Formoterol—Angina pectoris—Epirubicin—bone cancer	0.00222	0.00244	CcSEcCtD
Formoterol—Bronchitis—Epirubicin—bone cancer	0.00219	0.0024	CcSEcCtD
Formoterol—Nasopharyngitis—Doxorubicin—bone cancer	0.00218	0.00239	CcSEcCtD
Formoterol—Gastrointestinal disorder—Cisplatin—bone cancer	0.00218	0.00239	CcSEcCtD
Formoterol—Gastritis—Doxorubicin—bone cancer	0.00216	0.00237	CcSEcCtD
Formoterol—Pain—Cisplatin—bone cancer	0.00216	0.00237	CcSEcCtD
Formoterol—Upper respiratory tract infection—Epirubicin—bone cancer	0.00212	0.00232	CcSEcCtD
Formoterol—Conjunctivitis—Methotrexate—bone cancer	0.00211	0.00232	CcSEcCtD
Formoterol—Asthma—Doxorubicin—bone cancer	0.00211	0.00231	CcSEcCtD
Formoterol—Influenza—Doxorubicin—bone cancer	0.00211	0.00231	CcSEcCtD
Formoterol—Feeling abnormal—Cisplatin—bone cancer	0.00208	0.00228	CcSEcCtD
Formoterol—Haematuria—Methotrexate—bone cancer	0.00207	0.00227	CcSEcCtD
Formoterol—Hyperglycaemia—Epirubicin—bone cancer	0.00206	0.00226	CcSEcCtD
Formoterol—Angina pectoris—Doxorubicin—bone cancer	0.00205	0.00225	CcSEcCtD
Formoterol—Bronchitis—Doxorubicin—bone cancer	0.00203	0.00222	CcSEcCtD
Formoterol—CYP2A6—Fluoropyrimidine Activity—DHFR—bone cancer	0.00202	0.0227	CbGpPWpGaD
Formoterol—ADRB2—Arf6 signaling events—GNA11—bone cancer	0.00201	0.0227	CbGpPWpGaD
Formoterol—Body temperature increased—Cisplatin—bone cancer	0.00199	0.00219	CcSEcCtD
Formoterol—Conjunctivitis—Epirubicin—bone cancer	0.00197	0.00217	CcSEcCtD
Formoterol—Urinary tract infection—Epirubicin—bone cancer	0.00197	0.00217	CcSEcCtD
Formoterol—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00196	0.00215	CcSEcCtD
Formoterol—Haematuria—Epirubicin—bone cancer	0.00194	0.00213	CcSEcCtD
Formoterol—Pharyngitis—Methotrexate—bone cancer	0.00193	0.00212	CcSEcCtD
Formoterol—Urinary tract disorder—Methotrexate—bone cancer	0.00192	0.00211	CcSEcCtD
Formoterol—Urethral disorder—Methotrexate—bone cancer	0.00191	0.0021	CcSEcCtD
Formoterol—Sinusitis—Epirubicin—bone cancer	0.00191	0.00209	CcSEcCtD
Formoterol—Hyperglycaemia—Doxorubicin—bone cancer	0.0019	0.00209	CcSEcCtD
Formoterol—Visual impairment—Methotrexate—bone cancer	0.00188	0.00206	CcSEcCtD
Formoterol—Hypersensitivity—Cisplatin—bone cancer	0.00186	0.00204	CcSEcCtD
Formoterol—Rhinitis—Epirubicin—bone cancer	0.00183	0.00201	CcSEcCtD
Formoterol—Urinary tract infection—Doxorubicin—bone cancer	0.00183	0.002	CcSEcCtD
Formoterol—Conjunctivitis—Doxorubicin—bone cancer	0.00183	0.002	CcSEcCtD
Formoterol—Asthenia—Cisplatin—bone cancer	0.00181	0.00199	CcSEcCtD
Formoterol—Pharyngitis—Epirubicin—bone cancer	0.00181	0.00199	CcSEcCtD
Formoterol—Cardiac disorder—Methotrexate—bone cancer	0.00181	0.00198	CcSEcCtD
Formoterol—Urinary tract disorder—Epirubicin—bone cancer	0.0018	0.00198	CcSEcCtD
Formoterol—Oedema peripheral—Epirubicin—bone cancer	0.0018	0.00197	CcSEcCtD
Formoterol—Haematuria—Doxorubicin—bone cancer	0.00179	0.00197	CcSEcCtD
Formoterol—Connective tissue disorder—Epirubicin—bone cancer	0.00179	0.00197	CcSEcCtD
Formoterol—Urethral disorder—Epirubicin—bone cancer	0.00179	0.00196	CcSEcCtD
Formoterol—Sinusitis—Doxorubicin—bone cancer	0.00176	0.00193	CcSEcCtD
Formoterol—Immune system disorder—Methotrexate—bone cancer	0.00176	0.00193	CcSEcCtD
Formoterol—Visual impairment—Epirubicin—bone cancer	0.00176	0.00193	CcSEcCtD
Formoterol—Mediastinal disorder—Methotrexate—bone cancer	0.00176	0.00193	CcSEcCtD
Formoterol—CYP2A6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00175	0.0198	CbGpPWpGaD
Formoterol—Diarrhoea—Cisplatin—bone cancer	0.00173	0.00189	CcSEcCtD
Formoterol—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00171	0.0193	CbGpPWpGaD
Formoterol—Mental disorder—Methotrexate—bone cancer	0.00171	0.00187	CcSEcCtD
Formoterol—Malnutrition—Methotrexate—bone cancer	0.0017	0.00186	CcSEcCtD
Formoterol—Cardiac disorder—Epirubicin—bone cancer	0.00169	0.00186	CcSEcCtD
Formoterol—Rhinitis—Doxorubicin—bone cancer	0.00169	0.00186	CcSEcCtD
Formoterol—Pharyngitis—Doxorubicin—bone cancer	0.00167	0.00184	CcSEcCtD
Formoterol—Urinary tract disorder—Doxorubicin—bone cancer	0.00167	0.00183	CcSEcCtD
Formoterol—Oedema peripheral—Doxorubicin—bone cancer	0.00166	0.00182	CcSEcCtD
Formoterol—Dysgeusia—Methotrexate—bone cancer	0.00166	0.00182	CcSEcCtD
Formoterol—Connective tissue disorder—Doxorubicin—bone cancer	0.00166	0.00182	CcSEcCtD
Formoterol—Urethral disorder—Doxorubicin—bone cancer	0.00165	0.00181	CcSEcCtD
Formoterol—Immune system disorder—Epirubicin—bone cancer	0.00165	0.00181	CcSEcCtD
Formoterol—Mediastinal disorder—Epirubicin—bone cancer	0.00164	0.0018	CcSEcCtD
Formoterol—Back pain—Methotrexate—bone cancer	0.00164	0.0018	CcSEcCtD
Formoterol—Arrhythmia—Epirubicin—bone cancer	0.00163	0.00179	CcSEcCtD
Formoterol—Visual impairment—Doxorubicin—bone cancer	0.00163	0.00178	CcSEcCtD
Formoterol—Vomiting—Cisplatin—bone cancer	0.0016	0.00176	CcSEcCtD
Formoterol—Mental disorder—Epirubicin—bone cancer	0.0016	0.00175	CcSEcCtD
Formoterol—Rash—Cisplatin—bone cancer	0.00159	0.00175	CcSEcCtD
Formoterol—Dermatitis—Cisplatin—bone cancer	0.00159	0.00174	CcSEcCtD
Formoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00159	0.0179	CbGpPWpGaD
Formoterol—Malnutrition—Epirubicin—bone cancer	0.00159	0.00174	CcSEcCtD
Formoterol—Ill-defined disorder—Methotrexate—bone cancer	0.00157	0.00173	CcSEcCtD
Formoterol—Cardiac disorder—Doxorubicin—bone cancer	0.00157	0.00172	CcSEcCtD
Formoterol—Tension—Epirubicin—bone cancer	0.00156	0.00171	CcSEcCtD
Formoterol—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00156	0.0175	CbGpPWpGaD
Formoterol—Dysgeusia—Epirubicin—bone cancer	0.00155	0.00171	CcSEcCtD
Formoterol—Nervousness—Epirubicin—bone cancer	0.00154	0.00169	CcSEcCtD
Formoterol—Back pain—Epirubicin—bone cancer	0.00154	0.00168	CcSEcCtD
Formoterol—Malaise—Methotrexate—bone cancer	0.00153	0.00168	CcSEcCtD
Formoterol—Muscle spasms—Epirubicin—bone cancer	0.00153	0.00167	CcSEcCtD
Formoterol—Immune system disorder—Doxorubicin—bone cancer	0.00152	0.00167	CcSEcCtD
Formoterol—Mediastinal disorder—Doxorubicin—bone cancer	0.00152	0.00167	CcSEcCtD
Formoterol—Arrhythmia—Doxorubicin—bone cancer	0.00151	0.00165	CcSEcCtD
Formoterol—Nausea—Cisplatin—bone cancer	0.0015	0.00164	CcSEcCtD
Formoterol—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.0015	0.0169	CbGpPWpGaD
Formoterol—Cough—Methotrexate—bone cancer	0.00148	0.00162	CcSEcCtD
Formoterol—Mental disorder—Doxorubicin—bone cancer	0.00148	0.00162	CcSEcCtD
Formoterol—Ill-defined disorder—Epirubicin—bone cancer	0.00147	0.00162	CcSEcCtD
Formoterol—Malnutrition—Doxorubicin—bone cancer	0.00147	0.00161	CcSEcCtD
Formoterol—Agitation—Epirubicin—bone cancer	0.00146	0.0016	CcSEcCtD
Formoterol—ADRB2—GPCRs, Other—GRM1—bone cancer	0.00145	0.0164	CbGpPWpGaD
Formoterol—Myalgia—Methotrexate—bone cancer	0.00144	0.00158	CcSEcCtD
Formoterol—Arthralgia—Methotrexate—bone cancer	0.00144	0.00158	CcSEcCtD
Formoterol—Chest pain—Methotrexate—bone cancer	0.00144	0.00158	CcSEcCtD
Formoterol—Tension—Doxorubicin—bone cancer	0.00144	0.00158	CcSEcCtD
Formoterol—Dysgeusia—Doxorubicin—bone cancer	0.00144	0.00158	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00143	0.00157	CcSEcCtD
Formoterol—Malaise—Epirubicin—bone cancer	0.00143	0.00157	CcSEcCtD
Formoterol—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00143	0.0161	CbGpPWpGaD
Formoterol—Discomfort—Methotrexate—bone cancer	0.00143	0.00157	CcSEcCtD
Formoterol—Nervousness—Doxorubicin—bone cancer	0.00143	0.00157	CcSEcCtD
Formoterol—Back pain—Doxorubicin—bone cancer	0.00142	0.00156	CcSEcCtD
Formoterol—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00142	0.016	CbGpPWpGaD
Formoterol—Muscle spasms—Doxorubicin—bone cancer	0.00141	0.00155	CcSEcCtD
Formoterol—Palpitations—Epirubicin—bone cancer	0.0014	0.00154	CcSEcCtD
Formoterol—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00139	0.0156	CbGpPWpGaD
Formoterol—Cough—Epirubicin—bone cancer	0.00139	0.00152	CcSEcCtD
Formoterol—Anaphylactic shock—Methotrexate—bone cancer	0.00138	0.00152	CcSEcCtD
Formoterol—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00138	0.0155	CbGpPWpGaD
Formoterol—Infection—Methotrexate—bone cancer	0.00138	0.00151	CcSEcCtD
Formoterol—Hypertension—Epirubicin—bone cancer	0.00137	0.0015	CcSEcCtD
Formoterol—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00136	0.0154	CbGpPWpGaD
Formoterol—Ill-defined disorder—Doxorubicin—bone cancer	0.00136	0.0015	CcSEcCtD
Formoterol—Nervous system disorder—Methotrexate—bone cancer	0.00136	0.00149	CcSEcCtD
Formoterol—Arthralgia—Epirubicin—bone cancer	0.00135	0.00148	CcSEcCtD
Formoterol—Myalgia—Epirubicin—bone cancer	0.00135	0.00148	CcSEcCtD
Formoterol—Chest pain—Epirubicin—bone cancer	0.00135	0.00148	CcSEcCtD
Formoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.00135	0.0152	CbGpPWpGaD
Formoterol—Agitation—Doxorubicin—bone cancer	0.00135	0.00148	CcSEcCtD
Formoterol—Anxiety—Epirubicin—bone cancer	0.00135	0.00148	CcSEcCtD
Formoterol—Skin disorder—Methotrexate—bone cancer	0.00134	0.00148	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00134	0.00147	CcSEcCtD
Formoterol—Discomfort—Epirubicin—bone cancer	0.00134	0.00147	CcSEcCtD
Formoterol—Malaise—Doxorubicin—bone cancer	0.00132	0.00145	CcSEcCtD
Formoterol—Dry mouth—Epirubicin—bone cancer	0.00132	0.00145	CcSEcCtD
Formoterol—Palpitations—Doxorubicin—bone cancer	0.0013	0.00142	CcSEcCtD
Formoterol—Oedema—Epirubicin—bone cancer	0.0013	0.00142	CcSEcCtD
Formoterol—Anaphylactic shock—Epirubicin—bone cancer	0.0013	0.00142	CcSEcCtD
Formoterol—Hypotension—Methotrexate—bone cancer	0.00129	0.00142	CcSEcCtD
Formoterol—Infection—Epirubicin—bone cancer	0.00129	0.00141	CcSEcCtD
Formoterol—Cough—Doxorubicin—bone cancer	0.00128	0.00141	CcSEcCtD
Formoterol—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00128	0.0144	CbGpPWpGaD
Formoterol—Nervous system disorder—Epirubicin—bone cancer	0.00127	0.00139	CcSEcCtD
Formoterol—Hypertension—Doxorubicin—bone cancer	0.00127	0.00139	CcSEcCtD
Formoterol—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.00126	0.0143	CbGpPWpGaD
Formoterol—Tachycardia—Epirubicin—bone cancer	0.00126	0.00139	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00126	0.00138	CcSEcCtD
Formoterol—Skin disorder—Epirubicin—bone cancer	0.00126	0.00138	CcSEcCtD
Formoterol—Insomnia—Methotrexate—bone cancer	0.00125	0.00137	CcSEcCtD
Formoterol—Myalgia—Doxorubicin—bone cancer	0.00125	0.00137	CcSEcCtD
Formoterol—Arthralgia—Doxorubicin—bone cancer	0.00125	0.00137	CcSEcCtD
Formoterol—Chest pain—Doxorubicin—bone cancer	0.00125	0.00137	CcSEcCtD
Formoterol—Anxiety—Doxorubicin—bone cancer	0.00125	0.00137	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00124	0.00136	CcSEcCtD
Formoterol—Discomfort—Doxorubicin—bone cancer	0.00124	0.00136	CcSEcCtD
Formoterol—Dyspnoea—Methotrexate—bone cancer	0.00123	0.00135	CcSEcCtD
Formoterol—Somnolence—Methotrexate—bone cancer	0.00123	0.00135	CcSEcCtD
Formoterol—Dry mouth—Doxorubicin—bone cancer	0.00122	0.00134	CcSEcCtD
Formoterol—Dyspepsia—Methotrexate—bone cancer	0.00122	0.00134	CcSEcCtD
Formoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.00122	0.0137	CbGpPWpGaD
Formoterol—Hypotension—Epirubicin—bone cancer	0.00121	0.00133	CcSEcCtD
Formoterol—Oedema—Doxorubicin—bone cancer	0.0012	0.00132	CcSEcCtD
Formoterol—Anaphylactic shock—Doxorubicin—bone cancer	0.0012	0.00132	CcSEcCtD
Formoterol—Gastrointestinal disorder—Methotrexate—bone cancer	0.0012	0.00131	CcSEcCtD
Formoterol—Fatigue—Methotrexate—bone cancer	0.00119	0.00131	CcSEcCtD
Formoterol—Infection—Doxorubicin—bone cancer	0.00119	0.00131	CcSEcCtD
Formoterol—Pain—Methotrexate—bone cancer	0.00118	0.0013	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00118	0.0013	CcSEcCtD
Formoterol—Nervous system disorder—Doxorubicin—bone cancer	0.00118	0.00129	CcSEcCtD
Formoterol—Insomnia—Epirubicin—bone cancer	0.00117	0.00129	CcSEcCtD
Formoterol—Tachycardia—Doxorubicin—bone cancer	0.00117	0.00128	CcSEcCtD
Formoterol—Skin disorder—Doxorubicin—bone cancer	0.00116	0.00128	CcSEcCtD
Formoterol—ADRB1—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00116	0.013	CbGpPWpGaD
Formoterol—Dyspnoea—Epirubicin—bone cancer	0.00116	0.00127	CcSEcCtD
Formoterol—Somnolence—Epirubicin—bone cancer	0.00115	0.00126	CcSEcCtD
Formoterol—Feeling abnormal—Methotrexate—bone cancer	0.00114	0.00125	CcSEcCtD
Formoterol—Dyspepsia—Epirubicin—bone cancer	0.00114	0.00125	CcSEcCtD
Formoterol—Gastrointestinal pain—Methotrexate—bone cancer	0.00113	0.00124	CcSEcCtD
Formoterol—ADRB2—Arf6 signaling events—MET—bone cancer	0.00113	0.0128	CbGpPWpGaD
Formoterol—ADRB2—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00113	0.0128	CbGpPWpGaD
Formoterol—Hypotension—Doxorubicin—bone cancer	0.00112	0.00123	CcSEcCtD
Formoterol—Gastrointestinal disorder—Epirubicin—bone cancer	0.00112	0.00123	CcSEcCtD
Formoterol—Fatigue—Epirubicin—bone cancer	0.00112	0.00123	CcSEcCtD
Formoterol—Pain—Epirubicin—bone cancer	0.00111	0.00122	CcSEcCtD
Formoterol—Constipation—Epirubicin—bone cancer	0.00111	0.00122	CcSEcCtD
Formoterol—Urticaria—Methotrexate—bone cancer	0.0011	0.00121	CcSEcCtD
Formoterol—Abdominal pain—Methotrexate—bone cancer	0.00109	0.0012	CcSEcCtD
Formoterol—Body temperature increased—Methotrexate—bone cancer	0.00109	0.0012	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00109	0.0012	CcSEcCtD
Formoterol—Insomnia—Doxorubicin—bone cancer	0.00108	0.00119	CcSEcCtD
Formoterol—Dyspnoea—Doxorubicin—bone cancer	0.00107	0.00117	CcSEcCtD
Formoterol—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00107	0.012	CbGpPWpGaD
Formoterol—Feeling abnormal—Epirubicin—bone cancer	0.00107	0.00117	CcSEcCtD
Formoterol—Somnolence—Doxorubicin—bone cancer	0.00107	0.00117	CcSEcCtD
Formoterol—Gastrointestinal pain—Epirubicin—bone cancer	0.00106	0.00116	CcSEcCtD
Formoterol—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00106	0.0119	CbGpPWpGaD
Formoterol—Dyspepsia—Doxorubicin—bone cancer	0.00106	0.00116	CcSEcCtD
Formoterol—CYP2A6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00105	0.0118	CbGpPWpGaD
Formoterol—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00103	0.00114	CcSEcCtD
Formoterol—Fatigue—Doxorubicin—bone cancer	0.00103	0.00113	CcSEcCtD
Formoterol—Urticaria—Epirubicin—bone cancer	0.00103	0.00113	CcSEcCtD
Formoterol—Pain—Doxorubicin—bone cancer	0.00103	0.00112	CcSEcCtD
Formoterol—Constipation—Doxorubicin—bone cancer	0.00103	0.00112	CcSEcCtD
Formoterol—ADRB2—GPCRs, Other—SMO—bone cancer	0.00103	0.0116	CbGpPWpGaD
Formoterol—Body temperature increased—Epirubicin—bone cancer	0.00102	0.00112	CcSEcCtD
Formoterol—Abdominal pain—Epirubicin—bone cancer	0.00102	0.00112	CcSEcCtD
Formoterol—Hypersensitivity—Methotrexate—bone cancer	0.00102	0.00112	CcSEcCtD
Formoterol—Asthenia—Methotrexate—bone cancer	0.000993	0.00109	CcSEcCtD
Formoterol—Feeling abnormal—Doxorubicin—bone cancer	0.000988	0.00108	CcSEcCtD
Formoterol—Gastrointestinal pain—Doxorubicin—bone cancer	0.00098	0.00108	CcSEcCtD
Formoterol—Pruritus—Methotrexate—bone cancer	0.000979	0.00107	CcSEcCtD
Formoterol—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000974	0.011	CbGpPWpGaD
Formoterol—Hypersensitivity—Epirubicin—bone cancer	0.000954	0.00105	CcSEcCtD
Formoterol—Urticaria—Doxorubicin—bone cancer	0.000952	0.00104	CcSEcCtD
Formoterol—Abdominal pain—Doxorubicin—bone cancer	0.000948	0.00104	CcSEcCtD
Formoterol—Body temperature increased—Doxorubicin—bone cancer	0.000948	0.00104	CcSEcCtD
Formoterol—Diarrhoea—Methotrexate—bone cancer	0.000947	0.00104	CcSEcCtD
Formoterol—Asthenia—Epirubicin—bone cancer	0.00093	0.00102	CcSEcCtD
Formoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000928	0.0105	CbGpPWpGaD
Formoterol—Pruritus—Epirubicin—bone cancer	0.000917	0.00101	CcSEcCtD
Formoterol—Dizziness—Methotrexate—bone cancer	0.000915	0.001	CcSEcCtD
Formoterol—Diarrhoea—Epirubicin—bone cancer	0.000886	0.000973	CcSEcCtD
Formoterol—Hypersensitivity—Doxorubicin—bone cancer	0.000883	0.000969	CcSEcCtD
Formoterol—Vomiting—Methotrexate—bone cancer	0.00088	0.000966	CcSEcCtD
Formoterol—Rash—Methotrexate—bone cancer	0.000873	0.000958	CcSEcCtD
Formoterol—Dermatitis—Methotrexate—bone cancer	0.000872	0.000957	CcSEcCtD
Formoterol—Headache—Methotrexate—bone cancer	0.000867	0.000952	CcSEcCtD
Formoterol—Asthenia—Doxorubicin—bone cancer	0.00086	0.000944	CcSEcCtD
Formoterol—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000859	0.00968	CbGpPWpGaD
Formoterol—Dizziness—Epirubicin—bone cancer	0.000857	0.00094	CcSEcCtD
Formoterol—Pruritus—Doxorubicin—bone cancer	0.000848	0.000931	CcSEcCtD
Formoterol—Vomiting—Epirubicin—bone cancer	0.000824	0.000904	CcSEcCtD
Formoterol—Nausea—Methotrexate—bone cancer	0.000822	0.000902	CcSEcCtD
Formoterol—Diarrhoea—Doxorubicin—bone cancer	0.00082	0.0009	CcSEcCtD
Formoterol—Rash—Epirubicin—bone cancer	0.000817	0.000896	CcSEcCtD
Formoterol—Dermatitis—Epirubicin—bone cancer	0.000816	0.000896	CcSEcCtD
Formoterol—Headache—Epirubicin—bone cancer	0.000812	0.000891	CcSEcCtD
Formoterol—Dizziness—Doxorubicin—bone cancer	0.000793	0.00087	CcSEcCtD
Formoterol—Nausea—Epirubicin—bone cancer	0.00077	0.000844	CcSEcCtD
Formoterol—Vomiting—Doxorubicin—bone cancer	0.000762	0.000836	CcSEcCtD
Formoterol—Rash—Doxorubicin—bone cancer	0.000756	0.000829	CcSEcCtD
Formoterol—Dermatitis—Doxorubicin—bone cancer	0.000755	0.000829	CcSEcCtD
Formoterol—Headache—Doxorubicin—bone cancer	0.000751	0.000824	CcSEcCtD
Formoterol—Nausea—Doxorubicin—bone cancer	0.000712	0.000781	CcSEcCtD
Formoterol—ADRB1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000646	0.00729	CbGpPWpGaD
Formoterol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000646	0.00728	CbGpPWpGaD
Formoterol—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000637	0.00719	CbGpPWpGaD
Formoterol—ADRB2—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000632	0.00713	CbGpPWpGaD
Formoterol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000594	0.0067	CbGpPWpGaD
Formoterol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000589	0.00664	CbGpPWpGaD
Formoterol—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000586	0.00661	CbGpPWpGaD
Formoterol—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000581	0.00655	CbGpPWpGaD
Formoterol—ADRB2—Arf6 signaling events—EGFR—bone cancer	0.000573	0.00647	CbGpPWpGaD
Formoterol—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000524	0.0059	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—GRM4—bone cancer	0.000486	0.00548	CbGpPWpGaD
Formoterol—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000482	0.00543	CbGpPWpGaD
Formoterol—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000477	0.00538	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—GRM4—bone cancer	0.000476	0.00536	CbGpPWpGaD
Formoterol—CYP2A6—Biological oxidations—CYP3A4—bone cancer	0.000456	0.00514	CbGpPWpGaD
Formoterol—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	0.000451	0.00508	CbGpPWpGaD
Formoterol—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	0.000445	0.00502	CbGpPWpGaD
Formoterol—CYP2A6—NRF2 pathway—GSTP1—bone cancer	0.000445	0.00502	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—GRM1—bone cancer	0.000422	0.00475	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—GRM1—bone cancer	0.000412	0.00465	CbGpPWpGaD
Formoterol—CYP2A6—Biological oxidations—GSTP1—bone cancer	0.00039	0.0044	CbGpPWpGaD
Formoterol—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000331	0.00373	CbGpPWpGaD
Formoterol—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000302	0.0034	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—SMO—bone cancer	0.000297	0.00335	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—SMO—bone cancer	0.000291	0.00328	CbGpPWpGaD
Formoterol—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000278	0.00314	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—GRM4—bone cancer	0.000275	0.0031	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—RGS1—bone cancer	0.000275	0.0031	CbGpPWpGaD
Formoterol—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000274	0.00309	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—NDUFA12—bone cancer	0.000273	0.00308	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—GRM4—bone cancer	0.000269	0.00303	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—RGS1—bone cancer	0.000269	0.00303	CbGpPWpGaD
Formoterol—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000256	0.00288	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000254	0.00286	CbGpPWpGaD
Formoterol—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000252	0.00284	CbGpPWpGaD
Formoterol—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.00025	0.00282	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—GRM4—bone cancer	0.00025	0.00281	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—RGS1—bone cancer	0.00025	0.00281	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—RGS1—bone cancer	0.000244	0.00275	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—GRM4—bone cancer	0.000244	0.00275	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—GRM1—bone cancer	0.000238	0.00269	CbGpPWpGaD
Formoterol—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000238	0.00268	CbGpPWpGaD
Formoterol—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000235	0.00265	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—GRM1—bone cancer	0.000233	0.00263	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—NT5C3A—bone cancer	0.000227	0.00255	CbGpPWpGaD
Formoterol—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000219	0.00247	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000217	0.00245	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—GRM1—bone cancer	0.000216	0.00244	CbGpPWpGaD
Formoterol—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000216	0.00243	CbGpPWpGaD
Formoterol—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000214	0.00241	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—GRM1—bone cancer	0.000212	0.00239	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NDUFA12—bone cancer	0.000167	0.00188	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—GNA11—bone cancer	0.000154	0.00173	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000153	0.00173	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—SMO—bone cancer	0.000152	0.00172	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NDUFA12—bone cancer	0.000152	0.00171	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—GNA11—bone cancer	0.00015	0.00169	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—SMO—bone cancer	0.000149	0.00168	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GRM4—bone cancer	0.000147	0.00166	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—RGS1—bone cancer	0.000147	0.00166	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GRM4—bone cancer	0.000144	0.00163	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—RGS1—bone cancer	0.000144	0.00163	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—GNA11—bone cancer	0.000139	0.00157	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—IL3—bone cancer	0.000139	0.00157	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NT5C3A—bone cancer	0.000138	0.00156	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—GNA11—bone cancer	0.000136	0.00154	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—IL3—bone cancer	0.000136	0.00154	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GRM1—bone cancer	0.000128	0.00144	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NT5C3A—bone cancer	0.000127	0.00143	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL3—bone cancer	0.000126	0.00143	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NT5C3A—bone cancer	0.000126	0.00142	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GRM1—bone cancer	0.000125	0.00141	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL3—bone cancer	0.000124	0.00139	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ENO2—bone cancer	9.92e-05	0.00112	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—DHFR—bone cancer	9.21e-05	0.00104	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SMO—bone cancer	9e-05	0.00102	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SMO—bone cancer	8.81e-05	0.000993	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GNA11—bone cancer	8.6e-05	0.00097	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GNA11—bone cancer	8.24e-05	0.000929	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GNA11—bone cancer	8.06e-05	0.000908	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP3A4—bone cancer	7.8e-05	0.00088	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ATF1—bone cancer	7.66e-05	0.000863	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ATF1—bone cancer	7.49e-05	0.000845	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL3—bone cancer	7.47e-05	0.000842	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL3—bone cancer	7.3e-05	0.000824	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GSTP1—bone cancer	6.67e-05	0.000752	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TGFBR2—bone cancer	6.39e-05	0.00072	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TGFBR2—bone cancer	6.25e-05	0.000704	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ENO2—bone cancer	6.05e-05	0.000682	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IGF1R—bone cancer	6.01e-05	0.000678	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IGF1R—bone cancer	5.88e-05	0.000663	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—DHFR—bone cancer	5.61e-05	0.000633	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ENO2—bone cancer	5.56e-05	0.000628	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ENO2—bone cancer	5.52e-05	0.000622	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GNA11—bone cancer	5.25e-05	0.000592	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—DHFR—bone cancer	5.16e-05	0.000582	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—DHFR—bone cancer	5.12e-05	0.000577	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GNA11—bone cancer	4.82e-05	0.000544	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GNA11—bone cancer	4.78e-05	0.000539	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP3A4—bone cancer	4.76e-05	0.000536	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.73e-05	0.000534	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP3A4—bone cancer	4.37e-05	0.000493	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KIT—bone cancer	4.36e-05	0.000491	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP3A4—bone cancer	4.34e-05	0.000489	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.31e-05	0.000487	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KIT—bone cancer	4.26e-05	0.000481	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—BRAF—bone cancer	4.1e-05	0.000462	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTP1—bone cancer	4.07e-05	0.000459	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—BRAF—bone cancer	4.01e-05	0.000452	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—EGFR—bone cancer	3.97e-05	0.000448	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—EGFR—bone cancer	3.88e-05	0.000438	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTP1—bone cancer	3.74e-05	0.000422	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTP1—bone cancer	3.71e-05	0.000418	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTGS2—bone cancer	3.46e-05	0.00039	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MDM2—bone cancer	3.43e-05	0.000387	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MDM2—bone cancer	3.36e-05	0.000379	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—JUN—bone cancer	2.98e-05	0.000336	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—JUN—bone cancer	2.92e-05	0.000329	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MMP9—bone cancer	2.9e-05	0.000327	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MMP9—bone cancer	2.84e-05	0.00032	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EGFR—bone cancer	2.35e-05	0.000264	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EGFR—bone cancer	2.29e-05	0.000259	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTGS2—bone cancer	2.11e-05	0.000238	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TP53—bone cancer	1.97e-05	0.000222	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTGS2—bone cancer	1.94e-05	0.000219	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TP53—bone cancer	1.93e-05	0.000217	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTGS2—bone cancer	1.92e-05	0.000217	CbGpPWpGaD
